Sultan 2. Abdulhamid Training and Research Hospital
Istanbul, 34668, Turkey (Türkiye)
NCT Number: NCT05162248
In this study, we aimed to identify the different histopathological features of tumors with microsatellite instability (MSI) compared to microsatellite stable (MSS) in patients who underwent surgery for colorectal cancer. We also planned to determine how MSI affects prognostic parameters.
Looking for future studies?
Notify Me18 year–100 year
All sexes
Observational
Istanbul, 34668, Turkey (Türkiye)
According to Global Cancer Statistics, higher than 1.9 million new cases of colorectal cancer (CRC) and 935,000 deaths are estimated to occur in 2020, representing about one in 10 cancer cases and deaths. Overall, it ranks third in colorectal incidence but second in mortality.
In CRC evolution, the acquisition of genomic instability is a critical point, and there are at least two different pathways in the pathogenesis of CRC: the chromosomal instability (CIN) pathway (85%) and the microsatellite instability (MSI) pathway (15%).
Microsatellite instability (MSI) is a phenotype that occurs due to a malfunction in the DNA repair mechanism and is seen in approximately 15% of colorectal cancers (CRCs). CRCs with MSI have different clinical features, such as a tendency to settle in the proximal colon, poor differentiation, and more lymphocytic infiltration in the tumor. It has been shown that CRCs with MSI have a better prognosis and respond differently to chemotherapy than CRCs with microsatellite stable (MSS).
We aimed to evaluate the different histopathological features of tumors with MSI compared to MSS in patients who underwent surgery for colorectal cancer. We also planned to determine how MSI affects prognostic parameters such as mortality rate, recurrence, disease-free survival, cancer-specific survival, and overall survival.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Molecular analysis for Microsatellite Instability (MSI) status was performed using immunohistochemistry (IHC). IHC now recognized as an approved method to highly precision predict MSI in colorectal cancer.
Time frame: Five years
Overall survival is defined as the time interval from the time of primary operation to the date of all-cause death or the last follow-up.
Time frame: Five years
Disease-Free Survival is defined as the time interval from the time of primary operation to disease recurrence or death.
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Other
Clinicopathological Outcomes of Microsatellite Instability in Colorectal Cancer
Acronym: MSI-CRC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06428487
Colonic Diseases, Colorectal Cancer
Moscow, Russia
View Trial DetailsNCT04868773
CRC, Colonic Diseases
Orange, California, United States
View Trial DetailsNCT03366155
Colonic Diseases, Colorectal Adenocarcinoma
Bethesda, Maryland, United States
View Trial DetailsNCT03377361
Colonic Diseases, Colorectal Cancer
Birmingham, Alabama, United States
View Trial Details